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Ovarian cancer aﬀects approximately 25,000 women in the United States each year and remains one of the most lethal female
malignancies. A standard approach to therapy is surgical cytoreduction, after which the remaining microscopic residual disease is
treated with chemotherapy. The vast majority of patients have disease recurrence, underscoring the crucial need for approaches
to control the regrowth, or colonization, of tissues after local treatment. Improved therapies require mechanistic information
about the process of metastatic colonization, the ﬁnal step in metastasis, in which cancer cells undergo progressive growth at
secondary sites. Studies of metastasis suppressors are providing insights into events controlling metastatic colonization. This paper
reviews our laboratory’s approach to the identiﬁcation, characterization, and functional testing of the JNKK1/MKK4 metastasis
suppressor in ovarian cancer metastatic colonization. Speciﬁcally, we demonstrate that interaction of ovarian caner cells with the
omental microenvironment activates JNKK1/MKK4resulting in decreased proliferation without aﬀecting apoptosis. The potential
role of the omental microenvironment, speciﬁcally milky spot structures, is also described. It is our goal to provide this work as a
usable paradigm that will enable others to study metastasis suppressors in clinical and experimental ovarian cancer metastases.
1.Introduction
Management of metastatic ovarian cancer continues to be
a critical clinical problem. Ovarian cancer aﬀects close to
25,000 women yearly [1] and most patients have extensive
metastatic disease at the time of diagnosis. Ovarian cancer
metastasis is thought to result from exfoliation of tumor cells
from the ovary and/or direct extension onto the peritoneal
surfaces, the omentum, and the surface of organs such as
the liver and bowel. A standard approach to therapy is to
surgically remove surgically as much of the tumor(s) as
possible, a process known as surgical cytoreduction. This
technique, which leaves only microscopic residual disease,
is used in conjunction with chemotherapy. Unfortunately,
more than 80% of patients have cancer regrowth. These
dismal statistics show the need for improved understanding
of the process of metastatic colonization, the ﬁnal step in
metastasis, in which cancer cells undergo progressive growth
at secondary sites [2, 3] (see Figure 1). While invasion and
adhesion have been well studied, mechanisms regulating
metastatic colonization are largely unknown. Studies of
metastasis suppressors are providing insights into events
controlling metastatic colonization [4].
Remarkably, in 2000 when our laboratory began working
on metastasis suppressors in ovarian cancer, there were
only a handful of papers that speciﬁcally addressed aspects
of ovarian cancer metastasis. Not surprisingly, research in
the molecular underpinnings of ovarian cancer metastasis
continues to lag behind other cancer types. In addition
to fundamental aspects of metastasis, there are promising
developmentsintheareaoftherapeuticapplicationofmetas-
tasis suppressors. Work from the laboratories of Dr. Patricia
Steeg (National Cancer institute) and Dr. Dan Theodorescu
(University of Virginia) demonstrates the feasibility of taking2 Journal of Oncology
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Figure 1: Metastatic colonization is the ﬁnal step in the development of metastases. After lodging at 2◦ sites, cells can either remain
intravascular or extravasate. To form detectable metastases, disseminated cancer cells must activate signaling cascades, enabling them to
survive, enter the cell cycle, and divide. Progressive growth requires the fraction of proliferating cells to exceed the fraction of cells that are
nondividing or apoptotic,(Adapted from [4]).
metastasis suppressors into the clinic (reviewed in [5]).
The following sections describe our approach to using the
JNKK1/MKK4 metastasis suppressor to dissect molecular
events governing omental metastatic colonization in the
S K O V 3 i p . 1m o d e l .I ti so u rg o a lt oe n c o u r a g eo t h e r st o
examine metastasis suppressors in clinical and experimental
ovarian cancer metastases.
2.MetastasisSuppressorsCanBe Used to
Query the MetastaticProcess andRegulate
MetastaticGrowth
Clinically and experimentally, tumor formation and metas-
tasis are distinct processes. Locally growing tumors can
progress without the development of metastases. This obser-
vation prompted the hypothesis that molecular processes
regulating tumorigenicity and metastasis are distinguishable
and could be targeted therapeutically [4]. To identify events
speciﬁcally involved in metastasis regulation, our laboratory
and others hypothesized that genes and their encoded
proteins that speciﬁcally regulate metastasis formation could
be functionally identiﬁed [4–7]. Metastasis suppressors are
operationally deﬁned as genes which, when ectopically
expressed in metastatic cells, can inhibit the development of
spontaneous overt metastases without signiﬁcantly aﬀecting
primarytumorgrowth[4].Thisdeﬁnitionhasbeenextended
to include genes and their encoded proteins which speciﬁcally
inhibit metastatic colonization (i.e., experimental metastasis
formation using intravenous or intraperitoneal injection)
[4]. Identiﬁcation of metastasis suppressors requires in vivo
testing since in vitro assays generally do not model the
process of metastasis.
When eﬀorts to ﬁnd metastasis suppressors were initi-
ated, it was expected that their utility would be in predicting
disease outcome; however, robust in vivo studies have
showed that metastasis suppressors can control the growth
of cancer cells at metastatic sites [4, 8]. As a result there
now is evidence that metastasis suppressors can inﬂuence the
interaction of disseminated cells with the microenvironment
of distant organs and impair metastatic colonization. Inter-
estingly, other investigators, working on completely diﬀerent
questions, also identiﬁed metastatic colonization as a rate-
limiting step in metastasis formation [8, 9]. To date our
laboratory and others have identiﬁed 23 bona ﬁde metastasis
suppressors, many of which would not have been predicted
ap r i o r ibased on their previously known function(s) [4, 5].
Determining how metastasis suppressors modulate cancer
cell-microenvironmental interactions will shed light on their
function in metastatic colonization, a clinically tractable
therapeutic target [2, 10].
3. The JNKK1/MKK4 Stress-ActivatedKinase
HasaNovel MetastasisSuppressorFunction
Our laboratory identiﬁed c-Jun NH2-terminal kinase (JNK)
kinase 1/mitogen-activated protein kinase (MAPK) kinase 4
(JNKK1/MKK4)asaprostatecancermetastasissuppressorin
1999 [11] and subsequently as an ovarian cancer metastasis
suppressor in 2002 [12]. JNKK1/MKK4 is a MAP kinase
within the SAPK signaling cascade. MAP kinases occupy a
central position in cell growth, diﬀerentiation, and transfor-
mation. To date, three MAP kinase modules have been well
characterized: extracellular signal-regulated protein kinase
(ERK), c-Jun NH2-terminal protein kinase (JNK), and p38
[13]. Each consists of a MAP3K, a MAP2K, and a MAPK.
The JNK and p38 pathways are generally activated by stress
stimuli. The JNK signaling cascade consists of two MAP2Ks,
JNKK1,andMKK7,whilethep38signalingcascadeMAP2Ks
includes JNKK1, MKK3, and MKK6. JNKK1/MKK4 is a
dual-speciﬁcity kinase which, in response to extracellular
stimuli, can become activated and in turn can phosphorylate
and activate the JNK and p38 MAPKs (Figure 2 [2–4]).
In contrast, the MKK7 MAP2K can only phosphorylate
JNK, while the MKK3 and MKK6 MAP2Ks can only
phosphorylate p38.
Downstream targets of MAPK signaling include compo-
nents of the AP-1 transcription factor complex [14]. The
biological outcome of MAPK activation can depend, in part,
on the transcriptional regulation of target genes. Speciﬁcity
depends on factors such as cell type, cell environment, signal
strength and duration, and the particular composition of
the transcription factor, such as AP-1. While conventionalJournal of Oncology 3
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Figure 2: Overview of interactions in JNKK1/MKK4 signaling.
wisdom stipulates that the JNK and p38 pathways mediate
viability to stresses, increasing evidence from several model
systems indicates a role for both of these MAPKs in cell cycle
and consequent proliferation. For instance, reports demon-
strate important functions for JNK in the G1/S transition,
G2/M progression, and/or cytokinesis [15]. Similarly, p38
can activate the G2/M and spindle assembly checkpoints
in mammalian cells and delay entry into mitosis or may
prevent anaphase entry when the mitotic spindle is damaged
[16, 17]. In sum, the biological and biochemical functions
of JNKK1 were consistent with its putative role in metastasis
suppression;however,therewerenopublishedstudiestesting
its function in complex and dynamic pathological processes
such as metastasis. Comprehensive in vivo studies were
needed to test its role in metastasis regulation.
4. Testing the Abilityof JNKK1/MKK4
to SuppressOvarianCancer
MetastaticColonization
Various studies support a role for JNKK1/MKK4 dys-
regulation in clinical disease [2]. In ovarian cancer, the
relationship between its expression and metastasis has been
particularly informative. JNKK1/MKK4 protein levels were
signiﬁcantly decreased in metastases as compared to normal
ovarian surface epithelium [12]. Proﬁling studies identiﬁed
high JNKK1/MKK4 expression as a signiﬁcant predictor of
improved response to surgical cytoreduction [18]. In vivo
functional studies used SKOV3ip.1 human ovarian cancer
cells, which form metastatic deposits of a serious papillary
histology and produce highly reproducible numbers of
metastases on the omentum, liver, and bowel [12]. After
intraperitoneal injection of 1 × 106 parental SKOV3ip.1 or
SKOV3ip.1-vector control cells into female immunodeﬁcient
mice, the cells adhere to target organs and by 30 days post
injection (dpi) animals have ∼30 metastases. SKOV3ip.1
cells have low endogenous levels of JNKK1/MKK4 but
retain physiologic levels of other components of its signaling
cascade [12].
Ectopic JNKK1/MKK4 decreased the number of
SKOV3ip.1 metastases by 88% (P<. 0001) and increased
the animal lifespan by 70% (Wilcoxon, P = .0045) [12].
Its metastasis suppressor function is kinase-dependent
and studies showed that selective activation of p38 by
ectopic MKK6 reduced SKOV3ip.1 metastasis formation
by 70% (P = .0082), while selective activation of JNK
by ectopic MKK7 had no eﬀect (P = .43) (Figure 3, 3(a)
[19]). These data further deﬁned JNKK1/MKK4’s metastasis
suppressor activity and prompted the question—What
is the biological mechanism of JNKK1/MKK4-mediated
metastasis suppression?
5.Determiningthe BiologicalMechanism
of JNKK1/MKK4-Mediated
MetastasisSuppression
JNKK1/MKK4-mediated metastasis suppression could be
due to decreased adhesion of cells, increased apoptosis of
cells, or inhibition of cell proliferation. Quantitative real
time PCR showed that there was not a signiﬁcant diﬀerence
between the numbers of vector-only and JNKK1/MKK4-
expressing cells present on the omentum at 3 dpi (P = .06;
[20]). The TUNEL reaction was used to evaluate apoptosis
in SKOV3ip.1-vector or SKOV3ip.1-JNKK1/MKK4 micro-
scopic foci. This showed rare apoptotic cells (<1%) in both
groups (P = .43, Figure 4(a)). These data were conﬁrmed by
morphological assessment as well as immunohistochemistry
(IHC) for cleaved caspase 3, which is an early marker of
apoptosis [20]. To determine if SKOV3ip.1-JNKK1/MKK4
cellsweredeﬁcientinproliferation,incorporation ofBrdU(a
marker of S-phase cells) and endogenous levels of phospho-
histone H3 ((pH3), a marker of M-phase cells) were evalu-
ated in microscopic metastases [20]. These studies showed
that BrdU incorporation was decreased in SKOV3ip.1-
JNKK1/MKK4 cells (Figure 4; 6% versus 19% positive cells,
P<. 0001). Similarly, pH3 staining showed decreased
numbers of mitotic SKOV3ip.1-JNKK1/MKK4 cells (average
of 0.7% versus 2.5% positive cells in the SKOV3ip.1-vector
cells, P = .004) [20].
The decrease in BrdU incorporation and pH3-staining
in SKOV3ip.1-HA-JNKK1/MKK4 microscopic lesions sug-
gested that fewer cells were traversing S- and subsequently
M-phase compared to controls. This prompted the examina-
tion of cell cycle inhibitory proteins, including p21 and p27,
using IHC [20]. This showed a nearly 10-fold increase in p21
in SKOV3ip.1-JNKK1/MKK4 microscopic lesions in vivo as
compared to controls (average 9% versus 1%, P<. 0001,
Figure 4(c)). Since only a portion of the total population of
SKOV3ip.1 cells is in cell cycle at any point in time (with
19% entering S-phase in a 4-hour window), the observed
increaseinp21(9%ofthepopulation)isbiologicallyrelevant
[20]. The observation that JNKK1/MKK4 activation inhibits
disseminated cell growth prompted us to examine the extent
and duration of this suppression.
Despite the reduction in the number of SKOV3ip.1-
JNKK1/MKK4metastasesat30dpiandextensionofsurvival,
ultimately animals succumb to metastatic disease [20].4 Journal of Oncology
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Figure 3:SummaryoftheeﬀectofMKK7,JNKK1/MKK4,andMKK6onSKOV3ip.1metastasisformation.(a)SchematicofJNKK1/MKK4’s
signaling cascade. In vivo studies show that in SKOV3ip.1 cells, activation of p38 by ectopic expression of JNKK1/MKK4 or MKK6 causes
metastasis suppression. (b) Images depicting the eﬀect of speciﬁc proteins on metastasis formation, (Complete primary data can be found in
[12, 19]).
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Figure 4: SKOV3ip.1-JNKK1/MKK4 microscopic metastases show decreased proliferation. (a) TUNEL reaction for apoptotic cells was
quantitated and showed only rare positive cells. (b) Immunolabeling for BrdU in SKOV3ip1-vector and SKOV3ip.1-HA-JNKK1 microscopic
metastases(outlinedinblack)at14dpi(100 ×magniﬁcation).BothsizeandBrdUincorporationweresigniﬁcantlydecreasedinSKOV3ip.1-
JNKK1/MKK4 metastases compared to SKOV3ip.1-vector metastases. (c) p21 nuclear staining was signiﬁcantly decreased in SKOV3ip.1-
JNKK1/MKK4 metastases compared to SKOV3ip.1-vector metastases, (Data adapted from [20]).
A mathematical analysis of the rates of overt metastasis
formation suggested that suppression and outgrowth of
JNKK1/MKK4 cells are due to the behavior of the population
and not selection of a subset of cells, as would occur with
increased apoptosis or diﬀerential adhesion to the omentum
[20, 21]. Molecular analyses showed that overt metastases
stillexpressfunctionalJNKK1/MKK4,supportingthenotion
that metastasis formation was not due to selection for cells
that have permanently altered their JNKK1/MKK4 signaling
status [20]. Our accumulated data support a model in which
binding of cells to the omentum results in the activation
of JNKK1/MKK4 and induction of a cell cycle arrest [20].
In order to determine what cellular and molecular signals
activate JNKK1/MKK4 and how overt metastases ultimately
form, we must consider the microenvironment in which
suppression is taking place. In essence we are ahead of
ourselves and need to step back and consider what is
known about the structure, function, and morphology of
the omentum and integrate this knowledge into our current
understanding of JNKK1/MKK4-mediated suppression of
metastatic colonization.
6. Examiningthe StructureandFunction
of the Omentum and of
the Omental Microenvironment
The omentum, the primary site for ovarian cancer metas-
tases, is a fatty peritoneal fold that covers most of the
abdominal organs and serves as a storage site for lipids,
as a regulator of ﬂuid exchange, and as a reservoir for
immune cells [22]. Despite its importance, prevailing viewsJournal of Oncology 5
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Figure5:SKOV3ip.1-vectorandSKOV3ip.1-JNKK1/MKK4cellsarefoundinassociationwithimmunecellsearlyintheprocessofmetastatic
colonization.Histologyofomentaltissuesharvestedat3dpifrommice.A:immunecells;B:cancercells(demarcatedbyaddedgreenborder);
C: adipose; D: pancreatic tissue; E: vessels (Data adapted from [20]).
of ovarian cancer metastasis formation do not consider
the potentially dynamic and specialized functions that the
omentum may contribute to this process. Historically, the
omentum is viewed as being somewhat of an inert, black
box—malignant cells attach and cancer proliferates. The
implication is that ovarian cancer metastasis formation is
the result of uncontrolled growth of cancer cells and not a
regulated process which is in part controlled by the omental
microenvironment. A review of the literature challenges the
view that the omentum plays a passive role in ovarian cancer
metastasis formation.
The human and murine omenta are structurally simi-
lar, being composed of both adipose-rich and translucent
membranous tissues covered by a mesothelial layer [22].
Mesothelial cells share characteristics of both epithelial
and mesenchymal cell types and range from ﬂattened to
cuboidal in shape, depending on the body site or state
of activation [23, 24]. It is well established that omenta
from a wide variety of animals, including immunodeﬁcinet
rodents, contain aggregates of immune cells known as milky
spots. These were ﬁrst described by von Recklinghausen in
1863 [25] and termed “milky spots” by Ranvier in 1874
[26]. In the omentum, these structures are specialized to
enable mobilization of immune cells for migration into the
peritoneal cavity. They may also facilitate reentry of immune
cells from the peritoneum into the connective tissue (and
therefore bloodstream) [18,22–30].Remarkably,physiologic
functions of milky spots, or even their existence, have not
been integrated into generally accepted models of ovarian
cancer metastasis. This is a crucial oversight, as it does not
consider the possibility that ovarian cancer cells may exploit
a highly regulated physiologic system in order to adhere,
survive, and grow into metastases.
There is a limited amount of published data that suggests
that cancer cells can speciﬁcally interact with milky spot
structures [31, 32]. Interestingly, in our studies, Lotan et al.
found the association of SKOV3ip.1-vector and SKOV3ip.1-
JNKK1/MKK4 cells with immune aggregates which we
now suspect that they are milky spot structures (Figure 5
[20]). Our laboratory is currently investigating the potential
role for milky spot interactions in JNKK1/MKK4-mediated
suppression of metastatic colonization. We hypothesize that
disseminatedSKOV3ip.1cellsinteractwithmilkyspotsinthe
omentum, and these interactions contribute to the microen-
vironmentalcontext-dependentactivationofJNKK1/MKK4,
resulting in impaired metastatic colonization. Evidence for
speciﬁc interactions of ovarian cancer cells with milky spot
structures immediately identiﬁes a target for mechanism-
based studies of ovarian metastatic colonization.
7. Controlling Metastatic Growth by
TargetingOvarianCancer
MetastaticColonization
There is considerable interest in controlling the growth of
cancer cells at metastatic sites. Therapeutic leads may be
discerned by determining why disseminated cancer cells,
which have molecular modiﬁcations that should enable their
growth at distant sites, often lodge at target organs and
persist as undetectable, or dormant disease. Our data to
date support the hypothesis that activated JNKK1/MKK4
impairs proliferation of cells early in the course of metastatic
colonization. It is remarkable that few, if any, studies have
been conducted that speciﬁcally examine growth control of
cells during metastatic colonization. From the standpoint of
translational science, the crucial yet underexplored question
is how disseminated cells ultimately bypass suppression and
form progressively growing metastases.
Historically,thefundamentaltenetsofmetastasisbiology
dictate that acquisition of metastatic ability is the result of
the “drive” of malignant cells towards growth [21]. Thus it6 Journal of Oncology
was predicted that bypass of suppression is simply the result
of mutation-selection cycles which permanently inactivate
JNKK1 or members of its signaling cascade. Findings of
Lotan et al. and Hickson et al. challenge this paradigm and
suggest that JNKK1-mediated suppression may be due to
a reversible cell cycle arrest concomitant with changes in
JNKK1 activation status [20, 21]. These ﬁndings demon-
strate a crucial need to reexamine important but scattered
literature on population-dependent behaviors of metastatic
cells, which have heretofore been refractory to mechanistic
study [33–36]. This also presents an opportunity to examine
the interaction of ovarian cancer cells with their microen-
vironment of the omentum during metastatic colonization.
Given the rich literature on the bidirectional communication
between cancer cells and their microenvironments, it is
important that we consider microenvironmental functions
and adaptations as we examine the population-dependent
behaviors of cancer cells. Ultimately such studies can lay the
foundation for the development of adjuvant therapies that
can be used in conjunction with local therapy to delay the
onset of disease recurrence, extend survival, and improve
quality of life for patients with ovarian cancer.
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